Zobrazeno 1 - 10
of 128
pro vyhledávání: '"De la Rubia Nieto,A"'
Autor:
Gómez-Mateos, Magdalena, Valero-López, Adela, de la Rubia-Nieto, Teresa, Romero-López, María del Carmen, Díaz-Sáez, Victoriano
Publikováno v:
In Enfermedades Infecciosas y Microbiologia Clinica October 2014 32(8):491-496
Autor:
Belén Cabezuelo Escribano, Vicente Arocas Casañ, Beatriz Garrido-Corro, Pablo de la Cruz Murie, Mª José Blázquez Álvarez, M.ª Amelia de la Rubia Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 41, Iss 3, Pp 371-381 (2017)
Objetive: To describe off-label and unlicensed drugs in clinical practice in a Neonatal Intensive Care Unit (NICU).Method: The design of the study was a descriptive and retrospective three months research in a NICU of a Spanish University Hospital. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::28d6cdc128417def5091e85cc022bf68
https://doaj.org/article/a3a0337d94294e859a0e51f3b2f7e9f3
https://doaj.org/article/a3a0337d94294e859a0e51f3b2f7e9f3
Autor:
M Goicoechea-Diezhandino, JA García-Robles, JA Gimeno-Blanes, S Manrique-Rodríguez, María Sanjurjo-Sáez, C Pellicer-Franco, A de la Rubia-Nieto, Pernía-López
Publikováno v:
Expert Opinion on Orphan Drugs. 4:1199-1206
Objective: To describe an individualized therapeutic strategy in patients with Fabry disease receiving enzyme replacement therapy (ERT) with agalsidase beta, in order to find the minimum effective dose based on clinical outcomes and estimate its impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a75d0eabb4eb82043971f91126db2309
https://doi.org/10.1080/21678707.2016.1253468
https://doi.org/10.1080/21678707.2016.1253468
Autor:
Mª. Ángeles Fernández de Palencia Espinosa, Alberto Espuny Miró, Andrés Sánchez Salinas, Amelia de la Rubia Nieto, Ma Sacramento Díaz Carrasco
Publikováno v:
Journal of Oncology Pharmacy Practice. 23:443-453
Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug–drug interactions could be expected. Objectives To determine prevalence of clinically relevant drug–drug interactions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e2b587ac0f74f1151984a291c20485
https://doi.org/10.1177/1078155216664201
https://doi.org/10.1177/1078155216664201
Autor:
Vicente Arocas Casañ, Jaime Mateo Carmona, Olga García Molina, Mº Ángeles Fernández de Palencia Espinosa, Mª José Blázquez Álvarez Espinosa, Mª Amelia de la Rubia Nieto, Jesús del Río García
Publikováno v:
Farmacia Hospitalaria, Vol 40, Iss 2, Pp 63-78 (2016)
Objectives: To develop a procedure for management of off-label medications, and to analyze the treatments, indications, and hospital units which will request them more frequently, as well as which variables will have an impact on the authorization de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::3443d6b6d107018c47e48aa5c483cb18
http://www.aulamedica.es/fh/pdf/9268.pdf
http://www.aulamedica.es/fh/pdf/9268.pdf
Autor:
Vicente-Sánchez, Sergio, Olmos-Jiménez, Raquel, Ramírez-Roig, Cristina, García-Sánchez, María José, Valderrey-Pulido, Manuel, de la Rubia-Nieto, Amelia
Publikováno v:
Farmacia Hospitalaria, Volume: 42, Issue: 4, Pages: 147-151, Published: AUG 2018
Objective: To analyse the rate of therapeutic nonadherence in patients who experience early readmissions, and identify the factors associated with nonadherence. Methods: An observational descriptive 3-month study (March-May 2014), which included all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______624::a552af4748ea0b0ad7e688f047cfb5a1
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432018000400147&lng=en&tlng=en
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432018000400147&lng=en&tlng=en
Autor:
Sergio Vicente-Sánchez, Raquel Olmos-Jiménez, Cristina Ramírez-Roig, María José García-Sánchez, Manuel Valderrey-Pulido, Amelia de la Rubia-Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 42, Iss 4, Pp 147-151 (2018)
Analyze the frequency of therapeutic noncompliance in patients who suffer early readmissions, and identify the factors associated with it.Observational, descriptive study of three months duration (March - May 2014). All patients older than 65 years w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e38b7843e1113d05863bab7b5d4bc388
https://pubmed.ncbi.nlm.nih.gov/29959838
https://pubmed.ncbi.nlm.nih.gov/29959838
Autor:
APareja Rodriguez de Vera, S Vicente Sánchez, A De la Rubia Nieto, M Valderrey Pulido, ROlmos Jimenez, ARuiz Gómez, MDMRuiz Jimenez
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Efficacy of vancomycin in critical ill patients is highly related with adequate vancomycin blood levels, so a vancomycin protocol has been developed in a third-level hospital between the Pharmacy and the Intensive Care Unit (ICU) to achie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f7817d24ebc03b2178a2117a3533e3
https://europepmc.org/articles/PMC7535848/
https://europepmc.org/articles/PMC7535848/
4CPS-119 Effectiveness of capecitabine treatment in metastasic colorectal cancer in elderly patients
Autor:
F J Gómez Garcia, Mdm Ruiz Jimenez, S Vicente Sánchez, A Ruiz Gómez, MA de la Rubia Nieto, A Laorden Carrasco, JI García Soler, O García Molina, E González Lozano
Publikováno v:
Eur J Hosp Pharm
Background Age is the major risk factor for metastasic colorectal cancer (mCRC), with 70% of patients older than 70 years. Furthermore, elderly patients are not represented enough in cancer clinical trials, so there is a lack of information about the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02d62cec4f84926e7e19439bde3ebb4
https://doi.org/10.1136/ejhpharm-2018-eahpconf.210
https://doi.org/10.1136/ejhpharm-2018-eahpconf.210
Publikováno v:
Nutrición Hospitalaria, Vol 19, Pp 18-18 (2004)
Externí odkaz:
https://doaj.org/article/f022ecb5ec1945379e4386d23f9b7881